133 related articles for article (PubMed ID: 36016480)
1. Incentives to implement personalized medicine under second-best pricing.
Mougeot M; Naegelen F
Health Econ; 2022 Nov; 31(11):2411-2424. PubMed ID: 36016480
[TBL] [Abstract][Full Text] [Related]
2. Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Health Econ Rev; 2019 Oct; 9(1):28. PubMed ID: 31664604
[TBL] [Abstract][Full Text] [Related]
3. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
4. Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for Diagnostic Tests.
Robinson JC; Whaley C; Brown TT
JAMA Intern Med; 2016 Sep; 176(9):1353-9. PubMed ID: 27454826
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
6. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
7. Implementation of personalized medicine in a context of moral hazard and uncertainty about treatment efficacy.
Alcenat S; Maréchal F; Naegelen F
Int J Health Econ Manag; 2021 Mar; 21(1):81-97. PubMed ID: 33201335
[TBL] [Abstract][Full Text] [Related]
8. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
Critchley GJ; Zaric GS
Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
[TBL] [Abstract][Full Text] [Related]
9. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
Hu J; Mossialos E
Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
[TBL] [Abstract][Full Text] [Related]
11. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
[TBL] [Abstract][Full Text] [Related]
12. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
13. Paying for pharmaceuticals: uniform pricing versus two-part tariffs.
Brekke KR; Dalen DM; Straume OR
J Health Econ; 2022 May; 83():102613. PubMed ID: 35316701
[TBL] [Abstract][Full Text] [Related]
14. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
15. Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs.
Jiang Y; Li M; Jiang S; Si L; Gu Y
Value Health; 2024 Mar; 27(3):273-277. PubMed ID: 38042332
[TBL] [Abstract][Full Text] [Related]
16. Private versus social incentives for pharmaceutical innovation.
González P; Macho-Stadler I; Pérez-Castrillo D
J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
[TBL] [Abstract][Full Text] [Related]
17. Reference pricing with endogenous generic entry.
Brekke KR; Canta C; Straume OR
J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
[TBL] [Abstract][Full Text] [Related]
18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
19. Value-based differential pricing: efficient prices for drugs in a global context.
Danzon P; Towse A; Mestre-Ferrandiz J
Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
[TBL] [Abstract][Full Text] [Related]
20. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
Danzon PM; Towse A
Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
